Summary
Carzelesin is a cyclopropylpyrroloindole analogue which acts as a DNA-sequence-specific alkylating agent. In this phase I study, Carzelesin was given as a 4-weekly 10 min IV infusion to 51 patients with advanced solid tumours. Patients received a median of two courses (range 1–5) at one of nine dose levels: 24, 48, 96, 130, 150, 170, 210, 250 and 300 μg m–2. According to NCI-CTC criteria, non-haematological toxicities (grade 1/2) included fever, nausea and vomiting, mucositis and anorexia, none of which was clearly dose related. The dose-limiting toxicity was haematological and consisted mainly of neutropenia and to a lesser extent thrombocytopenia. From the dose level 150 μg m–2, the haematological toxicity (particularly thrombocytopenia) was delayed in onset, prolonged and cumulative in some patients. In several courses, double WBC nadirs occurred. The maximum tolerated dose for a single course was 300 μg m–2. From the dose level 170 μg m–2, the intended dose intensity could not be delivered to most patients receiving > 2 courses owing to cumulative haematological toxicity. The dose level with the best dose intensity for multiple courses was 150 μg m–2. The pharmacokinetics of Carzelesin and its metabolites (U-76,073; U-76,074) have been established in 31 patients during the first course of treatment using a HPLC method. Carzelesin exhibited linear pharmacokinetics. The concentration of U-76,074 (active metabolite) extended above the lower limit of quantitation (1 ng ml–1) for short periods of time and only at the higher dose levels. There was no relationship between neutropenia and the AUC of the prodrug Carzelesin, but the presence of detectable plasma levels of the active metabolite U-76,074 was usually associated with a substantial decrease in ANC values.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
D’Incalci, M. (1994). DNA-minor-groove alkylators, a new class of anticancer agents. Ann Oncol 5: 877–878.
EORTC-NDDO report (1992). Toxicology studies of Carzelesin (U-80244),
Fleming, G. F., Ratain, M. J., O’Brien, S. M., Schilsky, R. L., Hoffman, P. C., Richards, J. M., Vogelzang, N. J., Kasunic, D. A. & Earhart, R. H. (1994). Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst 86: 368–372.
Houghton, P. J., Cheshire, P. J., Hallman, J. D. n. & Houghton, J. A. (1995). Therapeutic efficacy of the cyclopropylpyrroloindole, Carzelesin, against xenografts derived from adult and childhood solid tumours. Cancer Chemother Pharmacol 36: 45–52.
Hurley, L. H., Reynolds, V. L., Swenson, D. H., Petzold, G. L. & Scahill, T. A. (1984). Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843–844.
Jonkman-de Vries, J. D., de Graaff-Teulen, J. A., Henrar, R. E. C., Kettenes-van-den-Bosch, J. J., Bult, A. & Beijnen, J. H. (1994). Pharmaceutical development of a parenteral formulation of the novel antitumour agent Carzelesin (U-80,244). Invest New Drugs 12: 303–314.
Lee, C. S. & Gibson, N. W. (1991). DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res 51: 6586–6591.
Li, L. H., DeKoning, T. F., Kelly, R. C., Krueger, W. C., McGovren, J. P., Padbury, G. E., Petzold, G. L., Wallace, T. L., Ouding, R. J., Prairie, M. D. & Gebhard, I. (1992). Cytotoxicity and antitumour activity of Carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res 52: 4904–4913.
McGovren, J. P., Clarke, G. L., Pratt, E. A. & DeKoning, T. F. (1984). Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot (Tokyo) 37: 63–70.
Reynolds, V. L., Molineux, I. J., Kaplan, D. J., Swenson, D. H. & Hurley, L. H. (1985). Reaction of the antitumor antibiotic CC-1065 with DNA location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 24: 6228–6237.
Sessa, C., Pagani, O., Zurlo, M. G., de Jong, J., Hofmann, C., Lassus, M., Marrari, P., Strolin Benedetti, M. & Cavalli, F. (1994). Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 5: 901–907.
Shamdas, G. J., Alberts, D. S., Modiano, M., Wiggins, C., Power, J., Kasunic, D. A., Elfring, G. L. & Earhart, R. H. (1994). Phase I study of adozelesin (U-73975) in patients with solid tumours. Anticancer Drugs 5: 10–14.
Van Tellingen, O., Pels, E. M., Henrar, R. E. C., Schaaf, L. J., Padbury, G. E., Beijnen, J. H. & Nooijen, W. J. (1994a). Fully automated high-performance liquid chromatographic method for the determination of Carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. J Chromatogr 652: 51–58.
Van Tellingen, O., Beijnen, J. H., Nooijen, W. J., van Oene, S., Henrar, R. E. C., Schaaf, L. J. & Padbury, G. E. (1994b). Plasma pharmacokinetics of Carzelesin (U-80,244) and metabolites (U-76,073, U-76,074) in mice and rats. Ann Oncol 5 (suppl 5): 171 (Abstract)
Van Tellingen, O., Punt, C. J. A., Awada, A., Wagener, D. J. T., Piccart, M. J., Groot, Y., Schaaf, L. J., Henrar, R. E. C., Nooijen, W. J. & Beijnen, J. H. (1998). A clinical pharmacokinetics study of Carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol 41: 377–384.
Warpehoski, M. A. & Hurley, L. H. (1988). Sequence selectivity of DNA covalent modification. Chem Res Toxicol 1: 315–333.
Wolf, I., Bench, K., Beijnen, J. H., Bruntsch, U., Cavalli, F., de Jong, J., Groot, Y., Van Tellingen, O., Wanders, J. & Sessa, C. (1996). Phase I clinical and pharmacokinetic study of Carzelesin (U-80,244) given on a daily × 5 schedule. Clin Cancer Res 2: 1717–1723.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Awada, A., Punt, C., Piccart, M. et al. Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. Br J Cancer 79, 1454–1461 (1999). https://doi.org/10.1038/sj.bjc.6690232
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690232
Keywords
This article is cited by
-
Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial
Journal of Gastrointestinal Cancer (2007)
